120 related articles for article (PubMed ID: 7720887)
1. The prognosis of stage III breast cancer treated with postoperative radiotherapy and adriamycin-based chemotherapy with and without tamoxifen. Eight year follow-up results of a randomized trial.
Saarto T; Blomqvist C; Tiusanen K; Gröhn P; Rissanen P; Elomaa I
Eur J Surg Oncol; 1995 Apr; 21(2):146-50. PubMed ID: 7720887
[TBL] [Abstract][Full Text] [Related]
2. The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial.
Blomqvist C; Tiusanen K; Elomaa I; Rissanen P; Hietanen T; Heinonen E; Gröhn P
Br J Cancer; 1992 Dec; 66(6):1171-6. PubMed ID: 1457360
[TBL] [Abstract][Full Text] [Related]
3. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.
Rivera E; Holmes FA; Buzdar AU; Asmar L; Kau SW; Fraschini G; Walters R; Theriault RL; Hortobagyi GN
Breast J; 2002; 8(1):2-9. PubMed ID: 11856154
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
Brito RA; Valero V; Buzdar AU; Booser DJ; Ames F; Strom E; Ross M; Theriault RL; Frye D; Kau SW; Asmar L; McNeese M; Singletary SE; Hortobagyi GN
J Clin Oncol; 2001 Feb; 19(3):628-33. PubMed ID: 11157012
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.
Jakesz R; Hausmaninger H; Haider K; Kubista E; Samonigg H; Gnant M; Manfreda D; Tschurtschenthaler G; Kolb R; Stierer M; Fridrik M; Mlineritsch B; Steindorfer P; Mittlböck M; Steger G
J Clin Oncol; 1999 Jun; 17(6):1701-9. PubMed ID: 10561206
[TBL] [Abstract][Full Text] [Related]
8. The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with > or = 10 positive axillary nodes.
Jabro G; Wazer DE; Ruthazer R; Lum R; Sklar N; Goldman D; Enegess D; Erban J
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):273-80. PubMed ID: 10760419
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
[TBL] [Abstract][Full Text] [Related]
10. No breast cancer subgroup can be spared postoperative radiotherapy after breast-conserving surgery. Fifteen-year results from the Swedish Breast Cancer Group randomised trial, SweBCG 91 RT.
Killander F; Karlsson P; Anderson H; Mattsson J; Holmberg E; Lundstedt D; Holmberg L; Malmström P
Eur J Cancer; 2016 Nov; 67():57-65. PubMed ID: 27614164
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.
Hortobagyi GN; Buzdar AU; Theriault RL; Valero V; Frye D; Booser DJ; Holmes FA; Giralt S; Khouri I; Andersson B; Gajewski JL; Rondon G; Smith TL; Singletary SE; Ames FC; Sneige N; Strom EA; McNeese MD; Deisseroth AB; Champlin RE
J Natl Cancer Inst; 2000 Feb; 92(3):225-33. PubMed ID: 10655439
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen versus chemotherapy as adjuvant treatment in stage III breast cancer.
Alagaratnam TT; Wong J
Aust N Z J Surg; 1986 Jan; 56(1):39-41. PubMed ID: 3090987
[TBL] [Abstract][Full Text] [Related]
13. The presence of proliferative breast disease with atypia does not significantly influence outcome in early-stage invasive breast cancer treated with conservative surgery and radiation.
Fowble B; Hanlon AL; Patchefsky A; Freedman G; Hoffman JP; Sigurdson ER; Goldstein LJ
Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):105-15. PubMed ID: 9747827
[TBL] [Abstract][Full Text] [Related]
14. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group.
Forrest AP; Stewart HJ; Everington D; Prescott RJ; McArdle CS; Harnett AN; Smith DC; George WD
Lancet; 1996 Sep; 348(9029):708-13. PubMed ID: 8806289
[TBL] [Abstract][Full Text] [Related]
15. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099.
Alvarez RH; Booser DJ; Cristofanilli M; Sahin AA; Strom EA; Guerra L; Kau SW; Gonzalez-Angulo AM; Hortobagyi GN; Valero V
Cancer; 2010 Mar; 116(5):1210-7. PubMed ID: 20082452
[TBL] [Abstract][Full Text] [Related]
18. The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation.
Levine MN; Bramwell V; Abu-Zahra H; Goodyear MD; Arnold A; Findlay B; Skillings J; Gent M
Br J Cancer; 1992 Jan; 65(1):130-2. PubMed ID: 1733435
[TBL] [Abstract][Full Text] [Related]
19. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer.
Pierce LJ; Hutchins LF; Green SR; Lew DL; Gralow JR; Livingston RB; Osborne CK; Albain KS
J Clin Oncol; 2005 Jan; 23(1):24-9. PubMed ID: 15545669
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
Tormey DC; Gray R; Gilchrist K; Grage T; Carbone PP; Wolter J; Woll JE; Cummings FJ
Cancer; 1990 Jan; 65(2):200-6. PubMed ID: 2403834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
